Three-pronged treatment for three-negative breast cancer (TNBC)! BMS and UbiVac partnered with cancer vaccine DPV-001/anti-OX40/anti-PD-1 triple therapy!

, June 10, 2020 /PRNewswire/ -- Cancer vaccine developer UbiVac and BMS have recently reached a clinical trial partnership to evaluate a pioneering cancer vaccine, DPV-001, developed using autophagy technologySafety, tolerance and initial efficacy of S immunooncology drug anti-OX40 therapy BMS-986178, as well as the continuation of anti-PD-1 therapy Opdivo (Odivo, generic name: nivolumab, navuliu monotag)the two sides will initiate a Phase Ib multicenter trial to test the hypothesis that a combination of DPV-001 cancer vaccines and anti-OX40 and anti-PD-1 therapy will enhance anti-cancer immunity in patients with advanced triple-negative breast cancer (TNBC)triple-negative breast cancer (TNBC) refers specifically to estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2) all negative expression of breast cancer, which is an invasive breast cancer, rapid progress, very poor prognosis, high recurrence rate, 5-year survival rate of less than 15%TNBC's ineffective ness in hormone therapy and HER2 targeted therapy, such as Herceptin, has limited clinical options, relying mainly on chemotherapyMetastatic TNBC is one of the most invasive and difficult to treat breast cancerTNBC tends to shift frequently and occurs in young patients (age 50) and in patients with inherited BRCA mutationsthe first clinical trial to combine a cancer vaccine (DPV-001) with a T-cell agonisant (BMS986178)Among them, DPV-001 is designed to educate the immune system to destroy cancer cells, AND BMS-986178 is designed to enhance the activity of the immune systemIn the trial, patients will also be treated with Opdivo, an anti-procedural death receptor-1 (PD-1) immunocheckpoint inhibitor designed to lift the brakes on the immune systemDr Bernard AFox, President and CEO of UbiVac,, said, "UbiVac is pleased to partner with The World Leader in Immune Oncology to study this innovative cancer vaccine in combination with anti-OX40 and checkpoint blocking, and to assess whether this program enhances the anti-cancer immunity of patients with advanced triple-negative breast cancerWe believe that this cutting-edge immunotherapy portfolio has the potential to induce long-term anticancer immunity and translate into a clinical response in patients with triple-negative breast cancer"
UbiVac's innovative Dribbles vaccine technologydeveloped on the DRibble vaccine platform, is a leading biologic for UbiVac, a protrusive cell (DC) targeted microfoly that contains short-life proteins that are considered to represent the dominant HLA on the surface of cancer cells These microvesis are packaged by a variety of TLR and NOD agonists, 15 DAMPs, and companion molecules The micro-follicle vaccine also contains more than 100 TNBC over-expressed proteins, as well as up to 1,700 variant peptide ligands (APL) that enhance immunity against cancer antigens This formula drives B-cells, CD4 and CD8 T cells, as well as the inherent components of the host immune system, to mediate anti-cancer functions in preclinical models, DPV-001 can convert "cold tumors" into "hot tumors" Cold tumor refers to the tumor tissue has no or only very few immune cells, while thermal tumor refers to the tumor tissue has immune cells immersion In the area of cancer treatment, it is important to convert "cold tumors" into "hot tumors" because many human tumors are thought to lack response to immunotherapy because of the lack of immune cells in tumor tissue that can identify cancer cells and are considered "cold" tumors "Based on these data, we believe that DRibble platform vaccine technology, combined with anti-OX40, will ignite the immune system in patients with "cold" tumors and transform them into "hot" tumors that are more sensitive to checkpoint inhibitors," said Dr Hong-Ming Hu, chief scientific officer at UbiVac, " (BioValleyBioon.com) original source: UbiVac Announces Clinical Trial With Bristol Myers Squibb on Combinationtherapy for Advanced Triple Negative Triple Negative Breast Cancer